Scope and Claims Analysis for US Patent 5,585,115 (Microcrystalline Cellulose Coprocessed With Silicon Dioxide)
US Patent 5,585,115 claims a specific excipient technology: microcrystalline cellulose (MCC) coprocessed with silicon dioxide (SiO₂) into particulate agglomerates where the SiO₂ is integrated with or partially coating the MCC, with quantified SiO₂ loading, particle size/surface area ranges, and downstream processing/form factors (wet granulation and incorporation into solids), plus dependent claims that broaden into active-containing compositions.
This is not a “process-only” cellulose patent. It is a composition-of-excipient patent with tight structural/physical limitations that can still cover many commercial excipient grades and many formulation routes, especially where SiO₂ is used as a flow aid, anti-adherent, or processing aid in MCC-based blends.
What is the core invention in US 5,585,115 and what do the independent claims actually require?
Independent claim 1: excipient agglomerate structure
Claim 1 requires all of the following elements:
- An excipient composition comprising:
- A particulate agglomerate of:
- microcrystalline cellulose (MCC) coprocessed with
- SiO₂ in about 0.1% to about 20% by weight “based on the weight of microcrystalline cellulose” (claim 4 narrows/clarifies this basis).
- MCC and SiO₂ are in intimate association.
- SiO₂ is integrated with or partially coating the MCC.
- The SiO₂ used to form the agglomerate is derived from SiO₂ having:
- average primary particle size from about 1 nm to about 100 μm.
This claim is best characterized as: MCC-anchored SiO₂ microagglomerates defined by (a) loading (0.1–20 wt%), (b) physical association (intimate association + integrated/coated), and (c) SiO₂ source particle size window (1 nm–100 μm).
Physical/structural limitations drive infringement scope
The “intimate association” and “integrated with or partially coating” language can narrow coverage if an alleged product is merely a physical blend of MCC and free-flow SiO₂ rather than a co-processed agglomerate where SiO₂ adheres to or coats MCC particles.
Independent claim 16: active-containing composition using the same excipient
Claim 16 builds on the excipient agglomerate and adds:
- From about 1% to about 99% of an excipient comprising the claimed MCC-SiO₂ agglomerate (same structural requirements as claim 1), plus
- From about 99% to about 1% of an active ingredient.
So claim 16 is an inclusion claim: any formulation with the claimed excipient range can be captured, regardless of the active’s identity, so long as it stays inside the compositional ranges.
Independent claim 22: “integrated” excipient rather than “agglomerate” framing
Claim 22 states:
- “particulate excipient of MCC integrated with” 0.1–20% SiO₂
- SiO₂ coprocessed with and partially coating MCC
- SiO₂ source defined by surface area 10 to 500 m²/g
Claim 22 shifts one key parameter: instead of “average primary particle size 1 nm–100 μm,” it uses surface area as the defining characteristic.
What do the dependent claims do to narrow or expand the scope?
SiO₂ particle size sub-ranges
- Claim 2: SiO₂ source primary particle size 5 nm to 40 μm.
- Claim 3: SiO₂ portion derived from colloidal silicon dioxide (often overlapping with very small primary particle size and high surface area grades).
- Claim 4–6: SiO₂ loading windows:
- 0.1–20 wt% (claim 4, basis clarification)
- 0.5–10 wt% (claim 5)
- 1.25–5 wt% (claim 6)
These dependent claims create a ladder of narrower capture ranges around common formulation loadings (notably ~1–5% is a frequent practical zone for flow/anti-adherent performance in MCC blends).
Particle size of the excipient/agglomerate
Claims 7–9 limit “excipient particles” average size:
- 10–1,000 μm (claim 7)
- 10–500 μm (claim 8)
- 30–250 μm (claim 9)
This creates product-form factor boundaries. Even if MCC-SiO₂ are intimately associated, a product with significantly different particle size distribution could avoid these narrower dependent claims (while still potentially falling under claim 1/16/22 if those narrower particle-size limits are not required).
Moisture content
- Claim 10: excipient particles have moisture content 0.5% to 15%.
This is formulation-state dependent. It can be relevant for infringement arguments where excipients are supplied in different moisture specs or dried/conditioned.
Additional excipient components
- Claim 11: the excipient particles further comprise at least one from:
- non-silicon metal oxides, starches, starch derivatives, surfactants, polyalkylene oxides, celluloses, cellulose ethers, cellulose esters, and mixtures.
This claim supports coverage where the MCC-SiO₂ agglomerate is part of a multi-component excipient rather than a two-component system.
SiO₂ surface area sub-ranges
- Claim 12: SiO₂ source surface area 10–500 m²/g.
- Claim 13: SiO₂ source surface area 175–350 m²/g (mid-range tighter band).
These dependent claims matter because many commercial SiO₂ grades are marketed by BET surface area. If an alleged MCC-SiO₂ product uses SiO₂ outside the stated BET/SAA bands, it can fall out of claim 22/claims 12–13-dependent capture, though it may still fall under claim 1/2/3 if primary particle size matches.
Bulk density
- Claim 14: bulk density 0.2–0.6 g/mL.
- Claim 15: bulk density 0.35–0.55 g/mL.
Bulk density is a physical handle for excipient powders and is often measured by suppliers. It is not required for the main structural claim 1, but it can become a critical feature in practice for dependent claim coverage.
Downstream processing and form factors
Multiple claims add process/form limitations:
- Claims 19 & 25: “wet granulated”
- Claim 19: wet granulated version of claim 16
- Claim 25: wet granulated version of claim 1
- Claims 20 & 29–30: wet granulated where the composition is also an active-containing composition.
- Claims 21 & 26: “incorporated into a solid form”
- Claims 27 & 28: wet granulated with an active agent; and with additional excipient member list.
In litigation terms, these claims can be used to argue coverage of specific manufacturing routes and final dosage-packaging states, but they still rely on the foundational MCC-SiO₂ co-processed agglomerate structure.
What is the effective claim “coverage map” for product categories?
1) Excipient-only products
Covered directly by claim 1 (and also claim 22 with surface area limitation), plus dependent claims that narrow to particle size, moisture, bulk density, and added co-excipients.
2) Excipient used in active blends
Covered by claim 16 (1–99% active) and dependent claims that require wet granulation or solid incorporation.
3) Wet granulated intermediates and finished solids
Covered by multiple dependent claims tied to wet granulation and solid form incorporation.
4) Excipient variants tied to particular SiO₂ grades
Coverage can attach to:
- SiO₂ primary particle size windows (claims 1–3)
- SiO₂ BET surface area windows (claims 12–13, and the independent claim 22 framework)
- SiO₂ loading windows (claims 4–6)
- Moisture and particle size windows (claims 7–10)
- Bulk density windows (claims 14–15)
Where is infringement most likely: “blend” vs “coprocessed agglomerate”?
The patent’s center of gravity is the phrase: SiO₂ is “integrated with or partially coating” MCC, and MCC and SiO₂ are in “intimate association”.
Products that are likely harder to defend against
- MCC-SiO₂ excipients marketed as coprocessed, agglomerated, pre-mixed for flow, or described as having SiO₂ adhered to MCC.
- Manufacturing routes that include a coprocessing step to form the agglomerate (wet or otherwise) that results in MCC particle surface coverage or integration.
Products that are likely lower risk for this patent (fact-dependent)
- Straight physical blends of MCC + free SiO₂ powders where characterization shows no meaningful coating/integration.
- Products where SiO₂ grade is outside the claimed primary particle size and the product’s defining SiO₂ characteristic is instead outside the claim 22 surface area window.
How does US 5,585,115 compare across excipient definition vs formulation definition?
Excipients vs formulations: two-layer coverage
- Claim 1 and 22 protect the excipient architecture itself.
- Claim 16 protects formulations containing that excipient architecture in any active range (1–99%).
This structure supports a licensing and enforcement strategy that targets both:
- excipient suppliers, and
- finished dosage manufacturers that select and incorporate the excipient into wet-granulated solids.
What patent landscape questions matter most around this specific patent?
Claim set likely sits in a typical MCC-excipient innovation cluster
US 5,585,115’s novelty is the MCC-SiO₂ coprocessed agglomerate and the quantified parameters that define the SiO₂ used. In practice, the surrounding landscape often includes:
- other MCC co-processed excipients,
- competing silicified celluloses,
- flow/anti-adherent and improved compaction grades,
- and later developments in granulation-friendly or direct compression excipients.
Litigation risk profile is usually driven by supplier disclosures
Because the claim turns on structural/physical properties, enforcement commonly depends on:
- supplier characterization reports,
- microscopy (surface coating/agglomerate morphology),
- particle size distribution (excipient and agglomerates),
- bulk density and moisture specs,
- and SiO₂ characterization (BET or primary particle size, depending on which claim path is asserted).
When does US 5,585,115 lose exclusivity, and what matters for enforcement timing?
This section cannot be completed correctly from the claim text alone.
A patent’s:
- statutory expiration (20-year term from earliest effective filing date),
- any PTA adjustments,
- any terminal disclaimers,
- and the existence of continuing applications
depend on bibliographic data not provided here.
Without that data, a definitive “expires on X date” timeline cannot be stated without risking factual error.
What would a freedom-to-operate (FTO) strategy look like for MCC-SiO₂ excipients using this patent as the anchor?
FTO should test claim 1 and claim 22 independently
- If the product is defined by SiO₂ primary particle size, evaluate against claim 1/2/3.
- If the product is defined by SiO₂ surface area, evaluate against claim 22/12/13.
Then test dependent parameters that are commonly specified in COAs
Common supplier specs map to:
- SiO₂ wt% (1.25–5% is frequently specified)
- excipient particle size distribution (30–250 μm bands are common in excipient marketing)
- moisture content and bulk density windows
- wet granulation compatibility and resulting solid dosage forms
In active formulations, check wet granulation and solid incorporation claims
If the commercial product is produced by wet granulation or results in a solid form using the claimed excipient architecture, dependent claims increase coverage options.
Which companies are likely implicated?
This cannot be answered accurately without reading the patent’s bibliographic record (assignee/inventors) and then mapping those assignees and their competitors through the Orange Book and excipient catalogs.
The claim text alone does not identify:
- assignee,
- cited references,
- related continuation patents,
- or specific dosage forms using the excipient.
Key Takeaways
- US 5,585,115 protects MCC–SiO₂ coprocessed excipient agglomerates where SiO₂ is integrated with or partially coating MCC and where SiO₂ source characteristics fall into defined windows: primary particle size (1 nm–100 μm) in claim 1 and surface area (10–500 m²/g) in claim 22.
- The claim set is structured to cover both excipient-only products (claim 1, claim 22) and active-containing formulations (claim 16), including wet granulated and solid form compositions.
- The most infringement-relevant factual issues are likely (a) co-processing vs simple blending and (b) whether SiO₂ meets the stated primary particle size or surface area definitions, plus formulation specs like SiO₂ loading, moisture, particle size, and bulk density for dependent claims.
FAQs
- How can “intimate association” and “partially coating” be proven in excipient infringement disputes?
- Do claim 1 and claim 22 cover different SiO₂ characterization methods (primary particle size vs surface area)?
- Can a formulation avoid claim 16 by changing the active loading outside 1–99%?
- How do wet granulation limitations in dependent claims affect enforcement against finished dosage manufacturers?
- What excipient COA parameters most directly map to dependent claims (moisture, bulk density, particle size)?
References
- U.S. Patent 5,585,115.
